Emerging medical devices for minimally invasive cell therapy.
The past decade has seen the first wave of cell-based therapeutics undergo clinical trials with varying degrees of success. Although attention is increasingly focused on clinical trial design, owing to spiraling regulatory costs, tools used in delivering cells and sustaining the cells' viability and functions in vivo warrant careful scrutiny. While the clinical administration of cell-based therapeutics often requires additional safeguarding and targeted delivery compared with traditional therapeutics, there is significant opportunity for minimally invasive device-assisted cell therapy to provide the physician with new regenerative options at the point of care. Herein we detail exciting recent advances in medical devices that will aid in the safe and efficacious delivery of cell-based therapeutics.
Department of Medicine, Center for Regenerative Therapeutics, and Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Cambridge, MA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA; School of Mechanical and Materials Engineering, University College Dublin, Dublin, Ireland.
Eoin D
ED
O'Cearbhaill
Department of Medicine, Center for Regenerative Therapeutics, and Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Cambridge, MA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA.
Kelvin S
KS
Ng
Department of Medicine, Center for Regenerative Therapeutics, and Department of Medicine, Division of Biomedical Engineering, Brigham and Women's Hospital, Harvard Medical School, Boston, MA; Harvard Stem Cell Institute, Cambridge, MA; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA. Electronic address: jeffkarp.bwh@gmail.com.
Jeffrey M
JM
Karp
D064987:Cell- and Tissue-Based Therapy / Q000295:instrumentation* / Q000639:trends*; D006801:Humans; D014481:United States
FDA; Induced Pluripotent Stem Cell; MSC; Mesenchymal Stem Cell; POZNAN; PTFE; Percutaneous Transvenous Transplantation of Autologous Myoblasts in the Treatment of Postinfarction Heart Failure; T1D; TOPCARE-AMI; Transplantation of Progenitor Cells and Regeneration Enhancement in Acute Myocardial Infarction; U.S. Food and Drug Administration; iPSC; polytetrafluoroethylene; type 1 diabetes